{"entity":{"id":"nct07489716","kind":"trial","name":"A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of SHR-1826 in non-small-cell lung cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.","summary":"A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07489716 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 90 participants planned, started 2026-04-29 and due to reach its primary completion in 2028-08. Interventions recorded: SHR-1826.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07489716","url":"https://clinicaltrials.gov/study/NCT07489716"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07489716","phase":"2","setting":"A Phase II Clinical Study on the Efficacy, Safety, and Pharmacokinetics of SHR-1826 for Injection in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","enrolled":90,"outcomes":[]},"route":"/trials/nct07489716/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}